This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie's Upadacitinib Meets Primary Endpoint in Phase IIb
by Zacks Equity Research
AbbVie's (ABBV) eczema candidate upadacitinib meets primary endpoints in a phase IIb trial for treating atopic dermatitis. The company aims to advance the candidate to the next study level in 2018.
Regeneron's Cemiplimab Gains Breakthrough Therapy Status
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi's skin cancer candidate cemiplimab gets the FDA-granted Breakthrough Therapy status. The companies also anticipate submitting a BLA in the first-quarter 2018.
Alnylam Shares Plunge on Patient Death, Dosing Suspended
by Zacks Equity Research
Alnylam (ALNY) announced suspension of dosing in all ongoing studies on its hemophilia candidate, fitusiran, following a patient's death in a phase II study.
4 Biotech Stocks to Improve Your Portfolio's Health
by Zacks Equity Research
The biotech industry has posted a turnaround in the first half of the year, despite facing pricing issues in 2016.
Lilly/Incyte to Re-File Baricitinib NDA Faster Than Expected
by Zacks Equity Research
Lilly (LLY) and Incyte announced that they will re-submit the new drug application (NDA) for their rheumatoid arthritis (RA) drug, baricitinib much faster than previously expected.
Amgen Presents New Repatha Analysis from FOURIER Study
by Zacks Equity Research
Amgen's (AMGN) new analysis from FOURIER study on Repatha showed that there was a strong progressive relationship between lower levels of bad cholesterol and a lower risk of cardiovascular events rates.
Can Sanofi (SNY) Sustain the Solid 1H Momentum in 2H17?
by Zacks Equity Research
Sanofi, Inc. (SNY) performed quite well in the first half of 2017 and looks well poised to carry on the momentum in the second half.
Top Stock Reports for Duke Energy, Stryker & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Duke Energy (DUK), Stryker (SYK) and Sanofi (SNY).
Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why
by Arpita Dutt
Late last week, Biogen (BIIB) and six other pharma and biotech stocks were in the news due to the pricing of their multiple sclerosis ("MS") drugs.
Pfizer's (PFE) Besponsa Gets FDA Nod with a Boxed Warning
by Zacks Equity Research
Pfizer, Inc.'s (PFE) leukemia candidate, Besponsa received FDA approval, though with a boxed warning on the label.
Seattle Genetics' Adcetris Granted Priority Review by FDA
by Zacks Equity Research
Seattle Genetics, Inc.'s (SGEN) supplemental Biologics License Application for Adcetris in patients with cutaneous T-cell lymphoma has been accepted by the FDA and granted priority review.
Regeneron's (REGN) RSV Drug Suptavumab Fails NURSERY Trial
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) announced disappointing results from a phase III study, NURSERY Pre-term on suptavumab .
Spectrum (SPPI) Initiates Phase II Study for Cancer Drug
by Zacks Equity Research
Spectrum Pharmaceuticals, Inc. (SPPI) initiated the registrational phase III study of qapzola in patients with non-muscle invasive bladder cancer (NMIBC) as per the FDA's requirement.
Shire Files Marketing Application for Lifitegrast in Europe
by Zacks Equity Research
Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.
Are Amgen's New Drugs Doing Well Enough to Drive Sales?
by Zacks Equity Research
Higher volumes of Amgen, Inc.'s (AMGN) new products may not be enough to offset the lost sales due to the decline in mature brands.
Pacira Pharmaceuticals Focuses on Exparel's Label Expansion
by Zacks Equity Research
Pacira Pharmaceuticals, Inc. (PCRX) is making efforts to expand its flagship product, Exparel, which was launched in 2012.
Novo Nordisk (NVO) Beats on Q2 Earnings, Revenues Miss
by Zacks Equity Research
Novo Nordisk A/S (NVO) beat earnings estimates but missed revenue estimates in Q2. Robust performance for Victoza and Tresiba will drive growth.
Forget Teva (TEVA), Buy These 4 Drug Stocks Instead
by Arpita Dutt
With generic drugmakers like Teva (TEVA) under pressure, here is a look at four drug stocks that look well-positioned.
Alnylam (ALNY) Q2 Loss Narrower than Expected, Sales Miss
by Zacks Equity Research
Alnylam's (ALNY) second-quarter results were mixed with the company reporting a narrower-than-expected loss but sales missed estimates.
Intrexon (XON) Q2 Loss Narrower than Expected, Revenues Miss
by Zacks Equity Research
Intrexon Corporation (XON) incurred narrower than expected loss and missed revenue estimates in Q2.
Catalyst (CPRX) Posts Narrower than Expected Loss in Q2
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) reported narrower than expected loss in Q2 and is focused on the development of its pipeline candidate Firdapse.
Forget Bayer, Buy These 3 Drug Stocks Instead
by Arpita Dutt
With Bayer (BAYRY) reporting mixed results in the second quarter and lowering its outlook, here is a look at 3 drug stocks which look well positioned.
VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y
by Zacks Equity Research
VIVUS reported dismal second-quarter results wherein its loss widened from the year-ago period on lower sales.
Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Emergent's (EBS) earnings and revenues miss estimates in Q2. However, revenue increased year-over-year due to product sales and increase in contract manufacturing revenues.
AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2
by Zacks Equity Research
AMAG Pharmaceuticals, Inc. (AMAG) posted narrower-than-expected loss and slightly beat revenue estimates in Q2.